Peptide Inhibitors That Block Collagen Secretion to Reduce Scarring
Peptide inhibitors targeting the TANGO1-cTAGE5 interaction reduced collagen secretion from cells and decreased scarring in zebrafish wound healing.
Quick Facts
What This Study Found
The peptide inhibitors specifically target the primary binding interface between TANGO1 and cTAGE5, two proteins required for collagen export from the endoplasmic reticulum. Treatment reduced protein levels of both TANGO1 and cTAGE5, blocking the secretion of multiple extracellular matrix components including collagens, fibrillin, and fibronectin.
In zebrafish, the peptide inhibitors altered tissue architecture and reduced granulation tissue formation during wound healing. In human dermal fibroblasts and cells from scleroderma patients (who have generalized fibrosis), the inhibitors reduced secretion of ECM proteins.
Key Numbers
- Reduced TANGO1 and cTAGE5 protein levels
- Inhibited secretion of collagens, fibrillin, and fibronectin
- Reduced granulation tissue in zebrafish wound healing
- Effective in human dermal fibroblasts and scleroderma patient cells
How They Did This
Researchers designed membrane-permeant peptide inhibitors targeting the TANGO1-cTAGE5 binding interface. They tested the peptides in cell culture (human dermal fibroblasts and scleroderma patient cells), measuring secretion of ECM proteins. In vivo testing used zebrafish cutaneous wound healing models to assess granulation tissue formation.
Why This Research Matters
Fibrotic diseases (lung fibrosis, liver cirrhosis, scleroderma, keloid scars) affect millions and have few effective treatments. Rather than targeting individual collagen types, this approach blocks the export machinery that all large ECM proteins share. This could be a broad-spectrum anti-fibrotic strategy.
The Bigger Picture
Fibrotic diseases (lung fibrosis, liver cirrhosis, keloid scars) affect millions with few treatments. Rather than targeting individual collagen types, this approach blocks the secretion machinery itself — potentially stopping all excessive collagen production.
What This Study Doesn't Tell Us
The in vivo data is from zebrafish, not mammals. Zebrafish wound healing differs from human scarring. The peptide inhibitors block secretion of multiple ECM proteins, not just collagen, which could cause off-target effects on normal tissue maintenance. Long-term safety of reducing ECM secretion is unknown. The peptides are membrane-permeant, but delivery to deep tissues in mammals would need optimization.
Questions This Raises
- ?Would blocking collagen secretion cause problems in normal wound healing?
- ?Can this approach be tested in mammalian fibrosis models?
Trust & Context
- Key Stat:
- Secretion machinery targeted Instead of blocking individual collagen types, these peptides target the cellular export system that all collagens use
- Evidence Grade:
- Rated preliminary: proof-of-concept study in cell culture and zebrafish. Needs mammalian in vivo testing.
- Study Age:
- Published in 2024. A novel therapeutic approach for fibrosis that is still in early development.
- Original Title:
- TANGO1 inhibitors reduce collagen secretion and limit tissue scarring.
- Published In:
- Nature communications, 15(1), 3302 (2024)
- Authors:
- Raote, Ishier, Rosendahl, Ann-Helen, Häkkinen, Hanna-Maria, Vibe, Carina, Küçükaylak, Ismail, Sawant, Mugdha, Keufgens, Lena, Frommelt, Pia, Halwas, Kai, Broadbent, Katrina, Cunquero, Marina, Castro, Gustavo, Villemeur, Marie, Nüchel, Julian, Bornikoel, Anna, Dam, Binita, Zirmire, Ravindra K, Kiran, Ravi, Carolis, Carlo, Andilla, Jordi, Loza-Alvarez, Pablo, Ruprecht, Verena, Jamora, Colin, Campelo, Felix, Krüger, Marcus, Hammerschmidt, Matthias, Eckes, Beate, Neundorf, Ines, Krieg, Thomas, Malhotra, Vivek
- Database ID:
- RPEP-09121
Evidence Hierarchy
Frequently Asked Questions
Can we prevent excessive scarring?
These peptide inhibitors blocked the cellular machinery that exports collagen, reducing scar tissue in zebrafish. This is a promising but very early approach.
What diseases could this treat?
Any condition involving excessive collagen production: lung fibrosis, liver cirrhosis, kidney fibrosis, keloid scars, and scleroderma.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09121APA
Raote, Ishier; Rosendahl, Ann-Helen; Häkkinen, Hanna-Maria; Vibe, Carina; Küçükaylak, Ismail; Sawant, Mugdha; Keufgens, Lena; Frommelt, Pia; Halwas, Kai; Broadbent, Katrina; Cunquero, Marina; Castro, Gustavo; Villemeur, Marie; Nüchel, Julian; Bornikoel, Anna; Dam, Binita; Zirmire, Ravindra K; Kiran, Ravi; Carolis, Carlo; Andilla, Jordi; Loza-Alvarez, Pablo; Ruprecht, Verena; Jamora, Colin; Campelo, Felix; Krüger, Marcus; Hammerschmidt, Matthias; Eckes, Beate; Neundorf, Ines; Krieg, Thomas; Malhotra, Vivek. (2024). TANGO1 inhibitors reduce collagen secretion and limit tissue scarring.. Nature communications, 15(1), 3302. https://doi.org/10.1038/s41467-024-47004-1
MLA
Raote, Ishier, et al. "TANGO1 inhibitors reduce collagen secretion and limit tissue scarring.." Nature communications, 2024. https://doi.org/10.1038/s41467-024-47004-1
RethinkPeptides
RethinkPeptides Research Database. "TANGO1 inhibitors reduce collagen secretion and limit tissue..." RPEP-09121. Retrieved from https://rethinkpeptides.com/research/raote-2024-tango1-inhibitors-reduce-collagen
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.